JP2014533095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533095A5 JP2014533095A5 JP2014520419A JP2014520419A JP2014533095A5 JP 2014533095 A5 JP2014533095 A5 JP 2014533095A5 JP 2014520419 A JP2014520419 A JP 2014520419A JP 2014520419 A JP2014520419 A JP 2014520419A JP 2014533095 A5 JP2014533095 A5 JP 2014533095A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- peptide
- group
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 150000001413 amino acids Chemical class 0.000 claims description 50
- 229940024606 amino acid Drugs 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 18
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 claims description 17
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 210000001808 exosome Anatomy 0.000 claims description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000002742 methionines Chemical group 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000024334 diffuse gastric cancer Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552817P | 2011-10-28 | 2011-10-28 | |
| US61/552,817 | 2011-10-28 | ||
| PCT/JP2012/006853 WO2013061594A1 (en) | 2011-10-28 | 2012-10-25 | Topk peptides and vaccines including the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016242382A Division JP6349560B2 (ja) | 2011-10-28 | 2016-12-14 | Ｔｏｐｋペプチドおよびそれを含むワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533095A JP2014533095A (ja) | 2014-12-11 |
| JP2014533095A5 true JP2014533095A5 (enExample) | 2015-12-03 |
| JP6124149B2 JP6124149B2 (ja) | 2017-05-10 |
Family
ID=48167445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520419A Active JP6124149B2 (ja) | 2011-10-28 | 2012-10-25 | Ｔｏｐｋペプチドおよびそれを含むワクチン |
| JP2016242382A Active JP6349560B2 (ja) | 2011-10-28 | 2016-12-14 | Ｔｏｐｋペプチドおよびそれを含むワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016242382A Active JP6349560B2 (ja) | 2011-10-28 | 2016-12-14 | Ｔｏｐｋペプチドおよびそれを含むワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9427461B2 (enExample) |
| EP (2) | EP2771350B1 (enExample) |
| JP (2) | JP6124149B2 (enExample) |
| KR (2) | KR102127211B1 (enExample) |
| CN (2) | CN104066746B (enExample) |
| AU (2) | AU2012329502B2 (enExample) |
| BR (2) | BR122021015246B1 (enExample) |
| CA (2) | CA3122778A1 (enExample) |
| DK (2) | DK3296317T3 (enExample) |
| ES (2) | ES2665576T3 (enExample) |
| IL (2) | IL231583B (enExample) |
| IN (1) | IN2014CN03922A (enExample) |
| MX (2) | MX380003B (enExample) |
| PH (1) | PH12014500720A1 (enExample) |
| RU (1) | RU2633503C2 (enExample) |
| SG (3) | SG10201608552WA (enExample) |
| TW (2) | TWI681973B (enExample) |
| UA (1) | UA114298C2 (enExample) |
| WO (1) | WO2013061594A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10277755B2 (en) * | 2016-02-29 | 2019-04-30 | Kyocera Document Solutions Inc. | Electronic device and marker processing method |
| CN114917189B (zh) | 2017-01-25 | 2024-05-14 | 奥塞免疫疗法公司 | 用于肽递送的稳定乳液的制造方法 |
| CA3101310A1 (en) * | 2018-03-12 | 2019-09-19 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
| WO2022066973A1 (en) * | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| US20240024438A1 (en) * | 2020-11-19 | 2024-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class peptides |
| CN117957012A (zh) * | 2021-07-19 | 2024-04-30 | 得克萨斯州大学系统董事会 | 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法 |
| CN114773480A (zh) * | 2022-06-07 | 2022-07-22 | 厦门大学附属翔安医院 | 一种抗topk第32位丝氨酸残基磷酸化的抗体 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| ATE319477T1 (de) | 1995-08-03 | 2006-03-15 | Univ Leiden | Antigen presentierende bläschen, die von zellen ableiten |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| CA2262006A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| ATE375362T1 (de) | 1998-06-25 | 2007-10-15 | Kyogo Itoh | Von cyclophilin b abstammende tumorantigen- peptide |
| AU2001296448A1 (en) * | 2000-10-03 | 2002-04-15 | Curagen Corporation | Tumor marker and methods of use |
| AU2002240818C1 (en) | 2001-03-14 | 2008-11-06 | Agilent Technologies, Inc. | MHC molecule constructs and their uses for diagnosis and therapy |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| US20060194199A1 (en) | 2002-09-30 | 2006-08-31 | Oncotherapy Science, Inc. | Method for diagnosing testicular seminomas |
| WO2005029067A2 (en) * | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| BRPI0613970B8 (pt) * | 2005-07-27 | 2021-05-25 | Oncotherapy Science Inc | composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34 |
| KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
| CA2660438A1 (en) | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| EP1972639A3 (en) * | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| TWI434853B (zh) * | 2007-04-11 | 2014-04-21 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| HUE032379T2 (en) * | 2007-07-27 | 2017-09-28 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| CA2940962C (en) * | 2007-12-05 | 2018-07-24 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
| JP2012501169A (ja) | 2008-08-27 | 2012-01-19 | オンコセラピー・サイエンス株式会社 | がん関連遺伝子ｌｇｎ／ｇｐｓｍ２ |
| CA2753681A1 (en) * | 2009-03-04 | 2010-09-10 | Oncotherapy Science, Inc. | Vangl1 peptides and vaccines including the same |
| TWI507204B (zh) * | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
-
2012
- 2012-10-25 CN CN201280065049.4A patent/CN104066746B/zh not_active Expired - Fee Related
- 2012-10-25 BR BR122021015246-2A patent/BR122021015246B1/pt active Search and Examination
- 2012-10-25 CN CN201711012299.2A patent/CN107759661B/zh not_active Expired - Fee Related
- 2012-10-25 EP EP12844519.4A patent/EP2771350B1/en active Active
- 2012-10-25 DK DK17198358.8T patent/DK3296317T3/da active
- 2012-10-25 SG SG10201608552WA patent/SG10201608552WA/en unknown
- 2012-10-25 JP JP2014520419A patent/JP6124149B2/ja active Active
- 2012-10-25 IN IN3922CHN2014 patent/IN2014CN03922A/en unknown
- 2012-10-25 UA UAA201404332A patent/UA114298C2/uk unknown
- 2012-10-25 WO PCT/JP2012/006853 patent/WO2013061594A1/en not_active Ceased
- 2012-10-25 AU AU2012329502A patent/AU2012329502B2/en not_active Ceased
- 2012-10-25 MX MX2018005104A patent/MX380003B/es unknown
- 2012-10-25 KR KR1020197026004A patent/KR102127211B1/ko not_active Expired - Fee Related
- 2012-10-25 EP EP17198358.8A patent/EP3296317B1/en active Active
- 2012-10-25 CA CA3122778A patent/CA3122778A1/en active Pending
- 2012-10-25 SG SG2014012363A patent/SG2014012363A/en unknown
- 2012-10-25 US US14/353,261 patent/US9427461B2/en active Active
- 2012-10-25 SG SG10201913173SA patent/SG10201913173SA/en unknown
- 2012-10-25 PH PH1/2014/500720A patent/PH12014500720A1/en unknown
- 2012-10-25 CA CA2852633A patent/CA2852633C/en active Active
- 2012-10-25 RU RU2014121502A patent/RU2633503C2/ru active
- 2012-10-25 ES ES12844519.4T patent/ES2665576T3/es active Active
- 2012-10-25 MX MX2014004875A patent/MX355759B/es active IP Right Grant
- 2012-10-25 BR BR112014009176-5A patent/BR112014009176B1/pt not_active IP Right Cessation
- 2012-10-25 KR KR1020147014201A patent/KR102020491B1/ko not_active Expired - Fee Related
- 2012-10-25 ES ES17198358T patent/ES2773699T3/es active Active
- 2012-10-25 DK DK12844519.4T patent/DK2771350T3/en active
- 2012-10-26 TW TW101139634A patent/TWI681973B/zh not_active IP Right Cessation
- 2012-10-26 TW TW105138804A patent/TWI617582B/zh not_active IP Right Cessation
-
2014
- 2014-03-19 IL IL231583A patent/IL231583B/en active IP Right Grant
-
2016
- 2016-05-30 IL IL245924A patent/IL245924B/en active IP Right Grant
- 2016-07-06 US US15/203,103 patent/US9849166B2/en active Active
- 2016-12-14 JP JP2016242382A patent/JP6349560B2/ja active Active
-
2017
- 2017-01-27 AU AU2017200530A patent/AU2017200530B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2464275C2 (ru) | Пептидные вакцины для раков, экспрессирующих опухолеспецифические антигены | |
| ES2545817T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1 | |
| JP2010506826A5 (enExample) | ||
| JP2014533095A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2010523471A5 (enExample) | ||
| US8663647B2 (en) | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides | |
| JP2012517799A5 (enExample) | ||
| TW200906850A (en) | TEM8 peptides and vaccines comprising the same | |
| JP2012520659A5 (enExample) | ||
| JP2016511221A5 (enExample) | ||
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| TWI627183B (zh) | 對於ｔｈ１細胞之ｃｄｃａ１抗原決定位胜肽及含此之疫苗 | |
| JP2015529219A5 (enExample) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| JP2012527867A5 (enExample) | ||
| JP2012526519A5 (enExample) | ||
| JP2014506114A5 (enExample) | ||
| RU2011130796A (ru) | Пептиды c1orf59 и содержащие их вакцины | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| JP2012513742A5 (enExample) | ||
| JP2013521761A5 (enExample) | ||
| JP2012522488A5 (enExample) | ||
| RU2015126849A (ru) | Пептиды sema5в и вакцины, содержащие эти пептиды | |
| RU2017106889A (ru) | Пептид, полученный из urlc10, и содержащая его вакцина |